Understand the source comparison
Do Peptides Help with Stroke Recovery?: Peptide Type Comparison
Cerebrolysin Neurotrophic factor mimicry, promotes synaptic reorganisation Acute phase (0–72 hours) Strong. Multiple RCTs, Cochrane review IV infusion (10–30mL daily) Best-evidenced peptide for acute stroke; modest but measurable functional improvements BPC-15
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- Neurotrophic factor mimicry, promotes synaptic reorganisation
- Acute phase (0–72 hours)
- Strong. Multiple RCTs, Cochrane review
- IV infusion (10–30mL daily)
- Best-evidenced peptide for acute stroke; modest but measurable functional improvements
- BPC-157
- Blood-brain barrier stabilisation, VEGF upregulation, reduces inflammation
- Acute to subacute (0–7 days)
- Moderate. Robust animal data, limited human trials
- Subcutaneous (200–500mcg daily)
- Promising neuroprotection profile; human data needed
- Dihexa
- HGF receptor activation, synaptogenesis promotion
- Subacute to chronic (weeks 2–12+)
- Emerging. Preclinical and TBI studies
- Oral (1–3mg daily)
- Potential for cognitive and motor recovery during neuroplasticity window
- P21
- STAT3 pathway activation, axonal sprouting
- Subacute (3 days to 3 months)
- Moderate. Animal models show accelerated motor recovery
- Intranasal or subcutaneous
- Enhances rehab outcomes when paired with physical therapy
- Thymalin
- Immune restoration, reduces post-stroke infection risk
- Acute to subacute (0–14 days)
- Moderate. Reduces infection-related complications
- Intramuscular (10mg daily)
- Addresses immunosuppression, indirect recovery benefit